Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,672 stopped studies mapped to Malignant Reproductive System Neoplasm and descendants · 89% state a reason
Over the 1,672 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive…(COMPASS) | Phase 4 | terminated | May 24, 2017 | North Eastern German Society of Gynaecological Oncology | A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the… | Enrollment / accrual |
| NCT04382898 | PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)(PRO-MERIT) | Phase 1 / Phase 2 | terminated | May 11, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT04298983 | Abemaciclib in Combination With Androgen Deprivation Therapy for Locally Advanced…(RAD 1805) | Phase 2 | terminated | Mar 6, 2020 | University of Alabama at Birmingham | Abemaciclib efficacy | Efficacy / futility |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 14, 2024 | Valerio Therapeutics | Business decision | Sponsor / business decision |
| NCT06643494 | Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical | Phase 1 / Phase 2 | suspended | Oct 16, 2024 | Optimal Health Research | PPI currently unable to continue. | Other (stated, no rule matched) |
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04696263 | Single-Port Versus Multi-Port Robotic Radical Prostatectomy | N/A | withdrawn | Jan 6, 2021 | Case Comprehensive Cancer Center | Study closure based on study population not found and not enough study staff | Other (stated, no rule matched) |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | Phase 3 | terminated | Jun 9, 2020 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Logistical problems impacting the speed of enrolment | Enrollment / accrual |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women… | — | withdrawn | Jul 22, 2022 | MetroHealth Medical Center | Personnel departure. | Other (stated, no rule matched) |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | Phase 1 / Phase 2 | withdrawn | Feb 6, 2023 | Centre Hospitalier Universitaire Vaudois | Lack of funding | Funding |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT04421222 | Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer(EPI-7386) | Phase 1 | terminated | Jun 9, 2020 | ESSA Pharmaceuticals | Study was terminated early due to a lack of improved efficacy. | Efficacy / futility |
| NCT05075577 | EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects… | Phase 1 / Phase 2 | terminated | Oct 13, 2021 | ESSA Pharmaceuticals | Study was terminated early due to a lack of improved efficacy. | Efficacy / futility |
| NCT05224869 | Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum… | N/A | terminated | Feb 4, 2022 | Icahn School of Medicine at Mount Sinai | Was not meeting target enrollment; other treatment options precluded completing study | Enrollment / accrual |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jun 23, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Feb 16, 2022 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test…(ACSCO) | Phase 3 | withdrawn | Aug 15, 2018 | Cordgenics, LLC | Slow enrollment | Enrollment / accrual |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | Phase 3 | terminated | Mar 5, 2019 | CR-CSSS Champlain-Charles-Le Moyne | Covid-19 pandemic | COVID-19 / pandemic |
| NCT06120972 | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known… | Phase 2 | withdrawn | Nov 7, 2023 | Alexander B Olawaiye, MD | Sponsor terminated due to Olaparib losing patent | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT02608359 | A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian… | — | withdrawn | Nov 18, 2015 | Johnson & Johnson Private Limited | No subjects recruited in the study | Enrollment / accrual |
| NCT05123300 | PRISMA-PET - Primary Staging of Prostate Cancer With PSMA | N/A | terminated | Nov 17, 2021 | Odense University Hospital | Due to change of EAU guidelines, where PSMA-PET/CT is now recommended for primary staging of… | Other (stated, no rule matched) |
| NCT03465579 | Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM)…(BIOPSTAGE) | N/A | terminated | Mar 14, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Patients in cohort 1 continued for prolonged periods given the difficulties encountered in the… | COVID-19 / pandemic |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant… | Phase 2 | terminated | Aug 15, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by the IRB due to low accrual, | Enrollment / accrual |
| NCT03891576 | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)(Newton) | Phase 2 | terminated | Mar 27, 2019 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic… | Phase 4 | terminated | Oct 22, 2019 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Phase 1 | withdrawn | Nov 8, 2024 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | Phase 4 | withdrawn | Oct 5, 2022 | Corewell Health East | Study withdrawn due to lack of funding and resources | Funding |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Phase 2 | terminated | Jul 6, 2021 | University of Washington | Withdrawal of funding | Funding |
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic… | Phase 2 | withdrawn | Dec 6, 2021 | Haider Mahdi | Per PI and agent sponsor | Other (stated, no rule matched) |
| NCT04072406 | A Self-Directed Mindfulness Meditation Intervention in Gynecologic Cancer Patients | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Covid-19 | COVID-19 / pandemic |
| NCT06752135 | Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a…(HRCC1) | — | terminated | Dec 30, 2024 | Azienda Policlinico Umberto I | Retrospectively data collection complited | Other (stated, no rule matched) |
| NCT03099499 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Phase 2 | terminated | Apr 4, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | Early Phase 1 | withdrawn | Mar 21, 2022 | Sir Mortimer B. Davis - Jewish General Hospital | Unable to obtain funding | Funding |
| NCT05709535 | PSMA-PET/CT Registry | — | terminated | Feb 2, 2023 | AHS Cancer Control Alberta | Not due to a safety concern; terminated early due to changing clinical trial landscape at centre | Safety / toxicity |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | — | terminated | Apr 18, 2017 | Gynesonics | Termination due to continued lack of patient compliance | Other (stated, no rule matched) |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1… | Phase 1 / Phase 2 | terminated | Jun 25, 2021 | Astellas Pharma Global Development, Inc. | The comprehensive assessment of other studies indicated the lack of significant monotherapy… | Other (stated, no rule matched) |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate… | Phase 1 / Phase 2 | terminated | Jun 23, 2023 | Oncternal Therapeutics, Inc | Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical… | Other (stated, no rule matched) |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | — | withdrawn | May 9, 2011 | Dr. Tamim Niazi | not stated | Not stated |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | — | withdrawn | Oct 27, 2015 | Sir Mortimer B. Davis - Jewish General Hospital | not stated | Not stated |
| NCT05826470 | Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of… | N/A | terminated | Apr 24, 2023 | Genesis Research LLC | Business decision of the Sponsor | Sponsor / business decision |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in…(REVOCAN) | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an… | Drug supply |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | — | withdrawn | Aug 28, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study never opened. | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 20, 2025source: clinicaltrials